25.23 USD
+0.27 (+1.06%)
25.23 USD
0 (0%)
Overall APLS gets a fundamental rating of 5 out of 10. We evaluated APLS against 531 industry peers in the Biotechnology industry. APLS has only an average score on both its financial health and profitability. APLS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, APLS could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
APLS had positive earnings in the past year.
APLS had a positive operating cash flow in the past year.
In the past 5 years APLS always reported negative net income.
APLS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
APLS has a better Return On Assets (4.25%) than 90.58% of its industry peers.
APLS has a better Return On Equity (11.21%) than 93.22% of its industry peers.
APLS has a better Return On Invested Capital (8.15%) than 93.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROIC | 8.15% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
APLS's Profit Margin of 4.43% is amongst the best of the industry. APLS outperforms 89.45% of its industry peers.
The Operating Margin of APLS (7.91%) is better than 90.40% of its industry peers.
With an excellent Gross Margin value of 88.85%, APLS belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
APLS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so APLS is destroying value.
APLS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for APLS has been increased compared to 5 years ago.
The debt/assets ratio for APLS has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.99, we must say that APLS is in the distress zone and has some risk of bankruptcy.
APLS's Altman-Z score of 0.99 is fine compared to the rest of the industry. APLS outperforms 61.39% of its industry peers.
The Debt to FCF ratio of APLS is 5.78, which is a neutral value as it means it would take APLS, 5.78 years of fcf income to pay off all of its debts.
APLS has a better Debt to FCF ratio (5.78) than 91.15% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that APLS is somewhat dependend on debt financing.
APLS's Debt to Equity ratio of 0.90 is on the low side compared to the rest of the industry. APLS is outperformed by 76.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Altman-Z | 0.99 |
ROIC/WACC0.94
WACC8.63%
2.3 Liquidity
A Current Ratio of 3.54 indicates that APLS has no problem at all paying its short term obligations.
APLS has a Current ratio of 3.54. This is comparable to the rest of the industry: APLS outperforms 41.05% of its industry peers.
APLS has a Quick Ratio of 3.10. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.10, APLS is not doing good in the industry: 61.39% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
APLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 116.40%, which is quite impressive.
Looking at the last year, APLS shows a very strong growth in Revenue. The Revenue has grown by 42.11%.
The Revenue has been growing by 127.23% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
3.2 Future
APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.97% yearly.
Based on estimates for the next years, APLS will show a quite strong growth in Revenue. The Revenue will grow by 13.78% on average per year.
EPS Next Y118.29%
EPS Next 2Y10.76%
EPS Next 3Y25.01%
EPS Next 5Y26.97%
Revenue Next Year28.85%
Revenue Next 2Y6.33%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 81.39 indicates a quite expensive valuation of APLS.
89.83% of the companies in the same industry are more expensive than APLS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of APLS to the average of the S&P500 Index (26.54), we can say APLS is valued expensively.
The Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 81.39 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 91.53% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of APLS indicates a rather cheap valuation: APLS is cheaper than 93.03% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.6 | ||
| EV/EBITDA | 38.18 |
4.3 Compensation for Growth
APLS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
APLS's earnings are expected to grow with 25.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.69
PEG (5Y)N/A
EPS Next 2Y10.76%
EPS Next 3Y25.01%
5. Dividend
5.1 Amount
APLS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.23
+0.27 (+1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.54%
Inst Owner Change-5.86%
Ins Owners3.7%
Ins Owner Change-0.16%
Market Cap3.19B
Revenue(TTM)1.02B
Net Income(TTM)44.99M
Analysts77.86
Price Target36.24 (43.64%)
Short Float %15.34%
Short Ratio6.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.57%
Min EPS beat(2)31.03%
Max EPS beat(2)38.1%
EPS beat(4)3
Avg EPS beat(4)-1.49%
Min EPS beat(4)-101.36%
Max EPS beat(4)38.1%
EPS beat(8)5
Avg EPS beat(8)-4.2%
EPS beat(12)7
Avg EPS beat(12)-3.46%
EPS beat(16)7
Avg EPS beat(16)-4.53%
Revenue beat(2)1
Avg Revenue beat(2)1.69%
Min Revenue beat(2)-7.17%
Max Revenue beat(2)10.55%
Revenue beat(4)2
Avg Revenue beat(4)-1.99%
Min Revenue beat(4)-16.4%
Max Revenue beat(4)10.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.73%
Revenue beat(12)7
Avg Revenue beat(12)7.96%
Revenue beat(16)10
Avg Revenue beat(16)42.21%
PT rev (1m)-6.37%
PT rev (3m)-5.96%
EPS NQ rev (1m)-8.56%
EPS NQ rev (3m)-29.05%
EPS NY rev (1m)1186.5%
EPS NY rev (3m)133.58%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-5.96%
Revenue NY rev (1m)2.88%
Revenue NY rev (3m)6.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 81.39 | ||
| Fwd PE | N/A | ||
| P/S | 3.14 | ||
| P/FCF | 40.6 | ||
| P/OCF | 40.48 | ||
| P/B | 7.96 | ||
| P/tB | 7.96 | ||
| EV/EBITDA | 38.18 |
EPS(TTM)0.31
EY1.23%
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)0.62
FCFY2.46%
OCF(TTM)0.62
OCFY2.47%
SpS8.03
BVpS3.17
TBVpS3.17
PEG (NY)0.69
PEG (5Y)N/A
Graham Number4.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.25% | ||
| ROE | 11.21% | ||
| ROCE | 10.32% | ||
| ROIC | 8.15% | ||
| ROICexc | 21.17% | ||
| ROICexgc | 21.17% | ||
| OM | 7.91% | ||
| PM (TTM) | 4.43% | ||
| GM | 88.85% | ||
| FCFM | 7.74% |
ROA(3y)-58.39%
ROA(5y)-59.14%
ROE(3y)-247.4%
ROE(5y)-257.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.7%
GM growth 5YN/A
F-Score7
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | 5.78 | ||
| Debt/EBITDA | 4.4 | ||
| Cap/Depr | 13.41% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 1.92 | ||
| Cash Conversion | 96.08% | ||
| Profit Quality | 174.81% | ||
| Current Ratio | 3.54 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 0.99 |
F-Score7
WACC8.63%
ROIC/WACC0.94
Cap/Depr(3y)54.61%
Cap/Depr(5y)218.08%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%463.04%
EPS Next Y118.29%
EPS Next 2Y10.76%
EPS Next 3Y25.01%
EPS Next 5Y26.97%
Revenue 1Y (TTM)42.11%
Revenue growth 3Y127.23%
Revenue growth 5YN/A
Sales Q2Q%132.98%
Revenue Next Year28.85%
Revenue Next 2Y6.33%
Revenue Next 3Y10.9%
Revenue Next 5Y13.78%
EBIT growth 1Y136%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year148.49%
EBIT Next 3Y34.96%
EBIT Next 5Y33.37%
FCF growth 1Y112.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y112.37%
OCF growth 3YN/A
OCF growth 5YN/A
APELLIS PHARMACEUTICALS INC / APLS FAQ
Can you provide the ChartMill fundamental rating for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to APLS.
Can you provide the valuation status for APELLIS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to APELLIS PHARMACEUTICALS INC (APLS). This can be considered as Fairly Valued.
What is the profitability of APLS stock?
APELLIS PHARMACEUTICALS INC (APLS) has a profitability rating of 5 / 10.
What are the PE and PB ratios of APELLIS PHARMACEUTICALS INC (APLS) stock?
The Price/Earnings (PE) ratio for APELLIS PHARMACEUTICALS INC (APLS) is 81.39 and the Price/Book (PB) ratio is 7.96.